A Single Quantifiable Viral Load Is Predictive of Virological Failure in Human Immunodeficiency Virus (HIV)-Infected Patients on Combination Antiretroviral Therapy: The Austrian HIV Cohort Study

Risk of virological failure in HIV-1-infected patients experiencing low-level viraemia under active antiretroviral therapy (ANRS C03 cohort study)

(2015) Marie-Anne Vandenhende et al.   ANTIVIRAL THERAPY

Any impact of blips and low-level viraemia episodes among HIV-infected patients with sustained virological suppression on ART?

(2015) Berta Pernas et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Factors Associated with Low-Level Viraemia and Virological Failure: Results from the Austrian HIV Cohort Study

(2015) Gisela Leierer et al.   PLoS One

Virological outcome and management of persistent low-level viraemia in HIV-1-infected patients: 11 years of the Swiss HIV Cohort Study

(2014) Noémie Boillat-Blanco et al.   ANTIVIRAL THERAPY

Antiretroviral Treatment of Adult HIV Infection

(2014) Huldrych F. Günthard et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Virologic Failure Following Persistent Low-level Viremia in a Cohort of HIV-Positive Patients: Results From 12 Years of Observation

(2013) C. Laprise et al.   CLINICAL INFECTIOUS DISEASES

Markers associated with persisting low-level viraemia under antiretroviral therapy in HIV-1 infection

(2013) L. Vancoillie et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Comparative Performances of HIV-1 RNA Load Assays at Low Viral Load Levels: Results of an International Collaboration

(2013) L. C. Swenson et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Cobas Ampliprep/Cobas TaqMan HIV-1 v2.0 Assay: Consequences at the Cohort Level

(2013) Ninon Taylor et al.   PLoS One

Plasma HIV-1 RNA Detection Below 50 Copies/mL and Risk of Virologic Rebound in Patients Receiving Highly Active Antiretroviral Therapy

(2012) T. Doyle et al.   CLINICAL INFECTIOUS DISEASES

Persistent low-level HIV-1 RNA between 20 and 50 copies/mL in antiretroviral-treated patients: associated factors and virological outcome

(2012) C. Charpentier et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Increased Risk of Virologic Rebound in Patients on Antiviral Therapy with a Detectable HIV Load

(2012) Timothy J. Henrich et al.   PLoS One

Antiretroviral Drug Resistance in HIV-1–Infected Patients Experiencing Persistent Low-Level Viremia During First-Line Therapy

(2011) Babafemi Taiwo et al.   JOURNAL OF INFECTIOUS DISEASES

HIV reservoirs and the possibility of a cure for HIV infection

(2011) S. Palmer et al.   JOURNAL OF INTERNAL MEDICINE

Short‐Course Raltegravir Intensification Does Not Reduce Persistent Low‐Level Viremia in Patients with HIV‐1 Suppression during Receipt of Combination Antiretroviral Therapy

(2010) D. McMahon et al.   CLINICAL INFECTIOUS DISEASES

Risk of Viral Failure Declines With Duration of Suppression on Highly Active Antiretroviral Therapy Irrespective of Adherence Level

(2010) Viviane D Lima et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Comparative RNA Quantification of HIV-1 Group M and Non-M With the Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 v2.0 and Abbott Real-Time HIV-1 PCR Assays

(2010) Jean-Marie Sire et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Detection of HIV-1 at between 20 and 49 Copies per Milliliter by the Cobas TaqMan HIV-1 v2.0 Assay Is Associated with Higher Pretherapy Viral Load and Less Time on Antiretroviral Therapy

(2010) J. F. Pascual-Pareja et al.   JOURNAL OF CLINICAL MICROBIOLOGY

The significance of very low-level viraemia detected by sensitive viral load assays in HIV infected patients on HAART

(2010) John Widdrington et al.   JOURNAL OF INFECTION

HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects

(2010) Maria J Buzón et al.   NATURE MEDICINE

Are previous treatment interruptions associated with higher viral rebound rates in patients with viral suppression?

(2009)   AIDS

Ultrasensitive assessment of residual HIV viraemia in HAART-treated patients with persistently undetectable plasma HIV-RNA: A cross-sectional evaluation

(2009) Stefano Bonora et al.   JOURNAL OF MEDICAL VIROLOGY

The Risk of Virologic Failure Decreases with Duration of HIV Suppression, at Greater than 50% Adherence to Antiretroviral Therapy

(2009) Michael Rosenblum et al.   PLoS One

Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy

(2008) S. Palmer et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA